M&T Bank’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

M&T Bank’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-784	Closed	-$10K	–	1689
2022 Q2	$10K	Buy	+784	New	+$12.4K	﹤0.01%	1559
2022 Q1	–	Sell	-911	Closed	-$55K	–	1663
2021 Q4	$55K	Sell	911 -102	-10%	-$7.63K	﹤0.01%	1523
2021 Q3	$95K	Hold	1,013	–	–	﹤0.01%	1489
2021 Q2	$168K	Hold	1,013	–	–	﹤0.01%	1483
2021 Q1	$195K	Buy	+1,013	New	+$253K	﹤0.01%	1431

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

M&T Bank's TLIS Position: Q3 2022 in Review

M&T Bank sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2022, closing a stake of 784 shares — an estimated $10K sold.

M&T Bank first reported a position in TLIS in Q1 2021 and held it in 5 quarters. The position peaked at $195K in Q1 2021. 29 funds tracked by Wall St. Rank hold TLIS as of Q3 2022.

M&T Bank reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2022 after selling out during the quarter.
M&T Bank sold 784 Talis Biomedical Corporation Common Stock shares in Q3 2022, an estimated $10K.
M&T Bank first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 5 quarters.
M&T Bank's Talis Biomedical Corporation Common Stock position peaked at $195K in Q1 2021.
29 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2022.

Based on M&T Bank's 13F filing for Q3 2022, filed 14 Nov 2022.